Nelson Christopher M. 4/A
4/A · QSAM Biosciences, Inc. · Filed Feb 14, 2024
Insider Transaction Report
Form 4/AAmended
Nelson Christopher M.
DirectorCEO
Transactions
- Conversion
Common Stock
2024-02-06$3.00/sh+8,683$26,049→ 182,000 total - Conversion
Series B Convertible Preferred Stock
2024-02-06→ 0 totalExercise: $3.00From: 2021-01-27→ Common Stock (8,683 underlying)
Footnotes (1)
- [F1]Correction to footnote: On February 13, 2024, the reporting person filed a Form 4 which inadvertently reported in footnote 1 that the date of the Exchange Agreements between the Issuer and all the Series B stockholders was 11/18/2023. It is hereby corrected that the Exchange Agreements were entered into between the dates of 10/16/2023 and 10/23/2023.